Giftify’s GLP-1 Play Delivered 916% Growth — Now They’re Scaling the Same Playbook to Sports, Healthcare, and Beyond

Yesterday, Giftify Inc. [NASDAQ: GIFT] announced a 916% uplift in pharmacy sales revenue following the launch of their powerful GLP-1 savings campaign. And now, they’re scaling up the same playbook to numerous other markets, starting with a sports tickets and merchandise savings campaign.

This is setting the popular gift card exchange operator up for exponential revenue growth in 2025 and beyond, adding further fuel to the fire of this significantly undervalued Nasdaq sleeper.

Here’s what you need to know.

Why Giftify Saw a 916% Boost off the Back of Its GLP-1 (Wegovy, Ozempic, Etc.) Smart Savings Program

By now, it’s no secret that GLP-1 weight loss medications like Ozempic and Wegovy are in hot demand, with everyone from Khloé Kardashian to Elon Musk touting the miracle drug. However, with an average cost of around $1000 per month, everyday consumers have been quick to seek out cheaper alternatives.

For a while, this saw companies like Hims & Hers Health [NYSE: HIMS] raking in massive revenues by offering cheaper alternatives. However, with GLP-1 medications currently under patent, discount off-brand alternatives, like what Hims & Hers offered, were only available under a particular loophole. That loophole allowed so-called “compounding pharmacies” to sell generic alternatives during an FDA-declared drug shortage.

However, that GLP-1 loophole has closed now that Novo Nordisk [NYSE: NVO] has ramped up its semaglutide production to meet demand. This has closed the loophole and left consumers with no other option but to buy genuine, brand-name GLP-1 drugs like Ozempic.

This is where Giftify Inc. [NASDAQ: GIFT] saw an opportunity to step in. With its flagship CardCash.com business already delivering discounted gift cards for popular pharmacies like Walgreens [NASDAQ: WBA] and CVS [NYSE: CVS], it seized the moment. Thus, we saw the launch of its smart savings solutions for GLP-1 weight loss medications campaign.

At its core, the campaign itself is relatively simple. Giftify’s CardCash.com platform was already delivering discounts that could exceed 10% on popular pharmacy gift cards. So the company set out to raise awareness among consumers that these discounted gift cards could, in fact, be used as a “hack” to obtain discounted GLP-1 medications.

Immediately, the campaign paid off, which leads us into yesterday’s announcement of a “916% week-over-week increase in the face value of gift cards sold across major pharmacy retailers.” However, while the company certainly seems pleased, with CEO Ketan Thakker emphatically announcing that “the response to our pharmacy gift card savings initiative has exceeded our expectations”, it isn’t stopping there.

Scaling up the GLP-1 Playbook to Healthcare, Sports, and Beyond

Presumably, Giftify [NASDAQ: GIFT] saw an immediate response to its GLP-1 savings campaign and quickly realized the power of the strategy. This seems to have led to a generalization of the strategy beyond its initial GLP-1 focus, with the company announcing the launch of an eerily similar campaign less than two weeks after its GLP-1 campaign launch.

This new campaign, which promotes CardCash.com as a sports tickets and merchandise savings platform, runs the same fundamental playbook as the GLP-1 campaign. That is, it sets out to raise consumer awareness that discounted gift cards from the likes of StubHub, Nike [NYSE: NKE], Dick’s Sporting Goods [NYSE: DKS], and others, are a viable route to obtaining discounts on sports tickets, merchandise, and apparel.

Further to this, Giftify also announced yesterday that it is now looking to put an “increased emphasis on its pharmacy gift card program to address the growing critical need for improved preventive care and affordable access to newer treatment options.” This strongly suggests that we’ll soon be seeing the same playbook applied to all manner of healthcare niches.

While the company has been light on specifics for now and has simply hinted at campaigns around “reduce prescription costs” and “broader healthcare accessibility”, it’s not hard to see where this could go. Just last year, the American Hospital Association noted that “nearly 30% of Americans haven’t taken their medication as prescribed due to high drug prices.” Clearly, the demand for the sorts of savings available on CardCash.com is there — the only thing missing is consumer awareness, which Giftify is now addressing.

However, as promising as all of this is, we’re really only seeing the tip of the iceberg for now. While healthcare and sports are indeed large markets, with a little creativity, Giftify could scale this same playbook up to a virtually unlimited number of markets. To take just one timely (albeit missed) opportunity, with spring break now in full swing, a “cut price cruise” campaign promoting, let’s say, the Carnival Cruise [NYSE: CCL] gift cards available on the CardCash.com platform could be wildly successful.

What Should Giftify Investors Expect Now?

What we’re seeing right now is essentially a sort of “aha moment” for Giftify [NASDAQ: GIFT] where it realizes that the business it has is significantly more powerful than previously thought. Previously, it was little more than a fun place to buy some cheap Christmas gift cards for those distant relatives you only saw once a year. But now, with this renewed consumer awareness strategy, CardCash.com looks to be transforming into a sort of hub for everyday living and entertainment expenses.

Of course, it’s still early days here, so how far Giftify can grow off the back of this playbook is yet to be seen. However, if a 916% uptick in category sales off the back of a single campaign is any indication, what we’ll see over the course of this year will be anything but insignificant.

Already, we’ve estimated that Giftify is undervalued by anywhere from 7x to 18x based on the strength of its current business alone, making it one of the more serious Nasdaq sleepers we’ve seen (although Giftify’s share price has ticked up slightly since then). However, should the company continue pushing consumer awareness with its latest playbook — a playbook that’s already delivered massive results — its future valuation will likely blow all expectations well out of the water.

__

(Featured image by Haberdoedas via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.